Browsing Tag
Keytruda
47 posts
Why eftilagimod alfa’s soft tissue sarcoma data now matters more than ever for Immutep Limited
Immutep Limited’s soft tissue sarcoma data may now define eftilagimod alfa’s future. Find out why this could reshape its oncology strategy.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears
Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA
Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA.
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.